California's Biomedical Industry Lays Out Opposition to SB771

Apr 04, 2007

∙ Paid

The chief lobbying group for the California biomedical industry Tuesday detailed its strong opposition to legislation that seeks to guarantee that California reaps an economic and health-related return on its $3 billion stem cell research investment.

David Gollaher, president of the 250-member organization, said the bill, SB771, will "create significant…

Keep reading with a 7-day free trial

Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.